Chondrial Therapeutics LLC is developing a drug for Friedreich’s Ataxia
Doctors with Chondrial Therapeutics LLC are on the verge of a human trial to test a delivery method of a protein called frataxin, which is used by each cell’s power plants—called mitochondria—to convert fat and sugar into energy. Friedreich’s Ataxia (FA) patients’ cells do not produce enough frataxin, causing the central nervous system breakdown.
After teaming up with Ron Bartek, founder of the Friedreich’s Ataxia Research Alliance, the research is on track for Phase 1 of the trials to begin in 2016. To read more about Chondrial Therapeutics LLC and their work with FA, click here.